Alpine Immune Sciences (NASDAQ:ALPN) Issues Quarterly Earnings Results

Alpine Immune Sciences (NASDAQ:ALPNGet Rating) issued its quarterly earnings results on Thursday. The biotechnology company reported ($0.25) EPS for the quarter, missing the consensus estimate of ($0.19) by ($0.06), Fidelity Earnings reports. Alpine Immune Sciences had a negative return on equity of 59.07% and a negative net margin of 214.70%.

Shares of NASDAQ:ALPN traded up $0.84 during trading on Friday, hitting $7.55. 92,046 shares of the stock were exchanged, compared to its average volume of 96,234. Alpine Immune Sciences has a 1-year low of $6.00 and a 1-year high of $15.14. The company’s fifty day simple moving average is $8.56 and its 200-day simple moving average is $10.01. The company has a debt-to-equity ratio of 0.03, a current ratio of 2.75 and a quick ratio of 2.75.

Several large investors have recently made changes to their positions in the company. BlackRock Inc. grew its holdings in shares of Alpine Immune Sciences by 33.1% during the 4th quarter. BlackRock Inc. now owns 728,848 shares of the biotechnology company’s stock worth $10,095,000 after purchasing an additional 181,066 shares in the last quarter. Vanguard Group Inc. boosted its stake in Alpine Immune Sciences by 1.4% in the 1st quarter. Vanguard Group Inc. now owns 707,598 shares of the biotechnology company’s stock valued at $6,347,000 after buying an additional 9,844 shares in the last quarter. State Street Corp boosted its stake in Alpine Immune Sciences by 4.2% in the 4th quarter. State Street Corp now owns 206,012 shares of the biotechnology company’s stock valued at $2,853,000 after buying an additional 8,216 shares in the last quarter. Geode Capital Management LLC boosted its stake in Alpine Immune Sciences by 1.4% in the 4th quarter. Geode Capital Management LLC now owns 196,666 shares of the biotechnology company’s stock valued at $2,723,000 after buying an additional 2,645 shares in the last quarter. Finally, Dimensional Fund Advisors LP boosted its stake in Alpine Immune Sciences by 5.4% in the 4th quarter. Dimensional Fund Advisors LP now owns 53,064 shares of the biotechnology company’s stock valued at $735,000 after buying an additional 2,700 shares in the last quarter. 77.00% of the stock is currently owned by institutional investors.

Several research analysts have commented on ALPN shares. Zacks Investment Research downgraded Alpine Immune Sciences from a “hold” rating to a “sell” rating in a research report on Tuesday, March 22nd. Oppenheimer dropped their price target on Alpine Immune Sciences from $19.00 to $17.00 in a research report on Monday, March 7th. Finally, HC Wainwright reissued a “buy” rating and set a $21.00 price objective on shares of Alpine Immune Sciences in a report on Friday.

About Alpine Immune Sciences (Get Rating)

Alpine Immune Sciences, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of protein-based immunotherapies for the treatment of cancer, autoimmune/inflammatory disorders, and other diseases. Its product pipeline includes ALPN-101, an inducible T cell costimulator (ICOS)/cluster of differentiation 28 (CD28) antagonist program for the treatment of autoimmune and inflammatory diseases; ALPN-202, a conditional CD28 costimulator and dual checkpoint inhibitor for the treatment of cancer; and ALPN-303, a dual B cell cytokine antagonist for the treatment of B cell-mediated inflammatory and autoimmune diseases.

Read More

Earnings History for Alpine Immune Sciences (NASDAQ:ALPN)

Receive News & Ratings for Alpine Immune Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alpine Immune Sciences and related companies with MarketBeat.com's FREE daily email newsletter.